title: Rehydrated lyophilized rifampicin-loaded mPEG-DSPE formulations for nebulization.
abstract: Rifampicin-loaded nanoparticles were prepared using two different molecular weights of poly-(ethylene oxide)-block-distearoyl phosphatidyl-ethanolamine (mPEG2000-DSPE and mPEG5000-DSPE) polymers. Particle sizes of all formulations studied were in the range of 162-395 nm. The entrapment efficiency (EE) was not affected by the copolymer's molecular weight, and the highest EE (100%) was obtained with drug to copolymer ratio of 1:5. The differential scanning calorimetry (DSC) thermograms showed Tg of rifampicin-loaded PEG-DSPE nanoparticles that shifted to a lower value, indicating entrapment of rifampicin in polymer matrix. The Fourier transformed infrared spectra revealed no chemical interactions between the drug and both copolymers. The in vitro drug release from the formulations occurred over 3 days and followed first-order release kinetic and Higuchi diffusion model. The nebulization of rehydrated lyophilized rifampicin mPEG-DSPE formulations had mass median aerodynamic diameter of 2.6 microm and fine particle fraction of 42%. The aerodynamic characteristic of the preparations was not influenced by the molecular weight of the copolymers. Therefore, it is suggested that both mPEG-DSPE are promising candidates as rifampicin carrier for pulmonary delivery.
authors.affiliation: Institute of Health, Sebha University, Sebha, Libya.
authors.forename: Juma Masoud Abdulla
authors.initials: JM
authors.lastname: Abdulla
authors.forename: Yvonne Tze-Fung
authors.initials: YT
authors.lastname: Tan
authors.forename: Yusrida
authors.initials: Y
authors.lastname: Darwis
mesh_terms: D000336:Aerosols / Q000138:chemical synthesis*; D000904:Antibiotics, Antitubercular / Q000737:chemistry; D003080:Cold Temperature; D004337:Drug Carriers / Q000138:chemical synthesis*; D004339:Drug Compounding / Q000379:methods; D004353:Drug Evaluation, Preclinical; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D010714:Phosphatidylethanolamines / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry*; D012293:Rifampin / Q000737:chemistry*; D014618:Vacuum; D014867:Water / Q000737:chemistry*
chemical_list: C519184:1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000); D000336:Aerosols; D000904:Antibiotics, Antitubercular; D004337:Drug Carriers; D010714:Phosphatidylethanolamines; D014867:Water; D011092:Polyethylene Glycols; D012293:Rifampin
references.citation: Chest. 1997 May;111(5):1168-73
references.pmid: 9149565
references.citation: Eur J Pharm Biopharm. 1999 Sep;48(2):101-11
references.pmid: 10469928
references.citation: Int J Pharm. 2001 Oct 9;228(1-2):53-67
references.pmid: 11576768
references.citation: J Control Release. 1998 Jan 23;51(1):13-22
references.pmid: 9685900
references.citation: Adv Drug Deliv Rev. 2008 May 22;60(8):863-75
references.pmid: 18308418
references.citation: Int J Pharm. 2001 Jul 31;223(1-2):15-27
references.pmid: 11451628
references.citation: Int J Antimicrob Agents. 2001 Sep;18(3):245-52
references.pmid: 11673037
references.citation: J Control Release. 2003 Aug 28;91(1-2):97-102
references.pmid: 12932641
references.citation: Biomaterials. 2002 Nov;23(22):4425-33
references.pmid: 12219833
references.citation: Int J Pharm. 2007 Feb 22;331(1):1-10
references.pmid: 17110063
references.citation: Adv Drug Deliv Rev. 2002 Feb 21;54(2):169-90
references.pmid: 11897144
references.citation: Int J Pharm. 2001 Mar 14;215(1-2):113-21
references.pmid: 11250097
references.citation: Biomaterials. 2003 Jun;24(13):2395-404
references.pmid: 12699677
references.citation: J Microencapsul. 1998 Jan-Feb;15(1):1-19
references.pmid: 9463803
references.citation: Eur J Pharm Sci. 2004 Jun;22(2-3):127-44
references.pmid: 15158898
references.citation: Pharm Res. 2000 Aug;17(8):955-61
references.pmid: 11028941
references.citation: J Control Release. 2005 Feb 2;102(2):373-81
references.pmid: 15653158
references.citation: Trends Biotechnol. 2007 Dec;25(12):563-70
references.pmid: 17997181
references.citation: J Control Release. 2004 Mar 5;95(2):239-48
references.pmid: 14980772
references.citation: Pulm Pharmacol Ther. 2005;18(2):151-3
references.pmid: 15649857
references.citation: Int J Pharm. 2004 Jan 9;269(1):37-49
references.pmid: 14698575
references.citation: FEBS Lett. 1994 Oct 10;353(1):71-4
references.pmid: 7926026
references.citation: Int J Pharm. 2001 Oct 9;228(1-2):5-17
references.pmid: 11576764
references.citation: Respir Care. 2000 Jun;45(6):652-66
references.pmid: 10894458
references.citation: Biomaterials. 2005 Nov;26(33):6736-42
references.pmid: 15935469
references.citation: J Antimicrob Chemother. 2001 Sep;48(3):431-4
references.pmid: 11533012
references.citation: Int J Pharm. 2002 Jan 1;231(1):97-106
references.pmid: 11719018
references.citation: Int J Pharm. 2007 Apr 4;334(1-2):71-7
references.pmid: 17113732
references.citation: J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3095-101
references.pmid: 17048523